Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlpha Growth Regulatory News (ALGW)

  • There is currently no data for ALGW

Acquisition

9 Sep 2024 07:00

RNS Number : 3305D
Alpha Growth PLC
09 September 2024
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Alpha Growth plc

("Alpha" or the "Company")

Acquisition of Jeometri Insurance Managers (Guernsey) Limited

Complementary Financial Services Company Strategic Acquisition

 

Alpha Growth plc (LSE: ALGW and OTCQB: ALPGF), a leading financial services specialist in life insurance-linked wealth and asset management, is pleased to announce that it has received regulatory approval and completed its strategic acquisition of 93.36% of the outstanding shares of Jeometri Insurance Managers (Guernsey) Limited ("Jeometri"), with the balance of the shares being retained by its founder and current director, Darren Wadley. Darren Wadley will be continuing as Managing Director of Jeometri and will be responsible for leading the business in its next phase of accelerated growth.

The consideration paid for the acquisition of Jeometri was ÂŁ449,321 in cash inclusive of the costs of the share acquisition and an infusion of working capital into the business. The transaction funding has been satisfied from Alpha's existing cash resources and no shares were issued by Alpha for the acquisition.

Joining the Alpha group of companies enhances Jeometri's visibility within the market place and provides it with the support required to accelerate its growth. With Jeometri's advanced solutions and its global clientele, we'll unlock significant opportunities for Alpha's life insurance businesses.

Moreover, Jeometri will deliver services currently provided by third parties for Alpha International Life Assurance Company in Guernsey. This strategic vertical integration will streamline operations, reduce costs, and enhance our efficiency, thereby boosting margins and overall performance for Alpha.

Gobind Sahney, Alpha's Chairman and CEO added: "We are very pleased to have received the Guernsey Financial Services Commission's change of control approval and to be able to expand our insurance services offering in Guernsey. This strategic acquisition represents a significant opportunity for growth, and we look forward to collaborating with Darren and his team to further grow Jeometri. Together, we aim to deliver complementary, value-enhancing support across the group's businesses.

We are also pleased to share that the group's 'buy strategy' is progressing well, and I look forward to updating our shareholders on our acquisition pipeline in due course.

The board of Alpha remains confident in our ability to achieve our goal of $2 billion in assets under management and administration in 2025. Achieving this goal will deliver significant improvements to both revenue and profitability."

** END **

For more information, please visit www.algwplc.com or contact the following:

 

Alpha Growth plc

+44 (0) 20 3959 8600

Gobind Sahney, Executive Chairman

info@algwplc.com

 

Allenby Capital Limited

+44 (0) 20 3328 5656

Amrit Nahal (Sales and Corporate Broking)

Nick Athanas / Piers Shimwell (Corporate Finance)

 

UK Investor Relations - Mark Treharne

ir@algwplc.com

 

About Alpha Growth plc

Specialist in Longevity Assets

Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets. Building on its well-established network, the Alpha Growth group has a unique position in the longevity asset services and investment business, as a listed entity with global reach. The group's strategy is to expand its advisory and business services via acquisitions and joint ventures in the UK and the US to attain commercial scale and provide holistic solutions to alternative institutional investors who are in need of specialised skills and unique access to deploy their financial resource in longevity assets.

Longevity Assets and Non-correlation

As a longevity asset, it is non-correlated to the real estate, equity capital and commodity markets. Its value is a function of time because as time passes the value gets closer to the face value of the policy. Hence creating a steady increase in the net asset value of the investment. This makes it highly attractive to investors wishing to counteract volatility within an investment portfolio and add yield.

Note: The Company only advises on and manages Longevity Assets that originate in the USA where the structured and life settlement market is highly regulated.

Forward Looking Statements Disclaimer

Certain statements, beliefs and opinions in this document are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward- looking statements, which speak only as of the date of this document. Readers should not treat the contents of this document as advice relating to legal, taxation or investment matters, and are to make their own assessments concerning these and other consequences, including the merits of information and the risks. Readers of this announcement are advised to conduct their own due diligence and agree to be bound by the limitations of this disclaimer.

Important Notice

The content of this announcement has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (FSMA). This announcement has been issued by and is the sole responsibility of the Company. The information in this announcement is subject to change.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQMZGGLGRZGDZZ
Date   Source Headline
2nd Apr 20257:00 amRNSHolding(s) in Company
2nd Apr 20257:00 amRNSDirector/PDMR Shareholding
27th Mar 20257:00 amRNS-RShareholder Update Call
25th Mar 20257:00 amRNSUnaudited Interim 2024 Annual Financial Report
19th Mar 20257:00 amRNSHolding(s) in Company
17th Mar 20253:42 pmRNSIntention to delist from London Stock Exchange
23rd Dec 20244:03 pmRNSNew Accounting Reference Date
12th Dec 202411:03 amRNSNon-Executive Director Appointment
27th Sep 20242:15 pmRNSHolding(s) in Company
17th Sep 20247:00 amRNSHalf-year Report
9th Sep 20247:00 amRNSAcquisition
25th Jun 20249:00 amRNSResult of AGM
6th Jun 20241:44 pmRNSHolding(s) in Company
17th May 20247:00 amRNSAcquisition Insurance Services Company
14th May 20243:39 pmRNSHolding(s) in Company
30th Apr 20241:00 pmRNSAnnual Financial Report
22nd Dec 20239:00 amRNSExpiration of Warrants
13th Dec 20237:00 amRNSAlpha International Life Receives KBRA Rating
14th Nov 20233:36 pmRNSJason Sutherland Receives Industry Recognition
9th Oct 20234:00 pmRNSHolding(s) in Company
9th Oct 20232:43 pmRNSHolding(s) in Company
29th Sep 202311:00 amRNSHalf-year Report
14th Aug 20236:29 pmRNSHolding(s) in Company
19th Jun 20237:00 amRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM
15th May 20237:00 amRNSAcquisition of Minority Holding and Share Issuance
3rd May 20237:00 amRNSHolding(s) in Company
2nd May 20237:00 amRNS2022 Annual Report & Financial Statements
15th Mar 20237:00 amRNSWarrant Exercise and Total Voting Rights
6th Mar 20237:00 amRNS2022 Annual Recap and Fund Results
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20231:10 pmRNSHolding(s) in Company
20th Jan 20232:05 pmRNSSecond Price Monitoring Extn
20th Jan 20232:00 pmRNSPrice Monitoring Extension
20th Jan 202311:05 amRNSSecond Price Monitoring Extn
20th Jan 202311:00 amRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSFurther Regarding Havelet Acquisition
6th Dec 20227:00 amRNSCompletion of Share Purchase Acquisition
17th Nov 20227:00 amRNSFinancial Services Company Acquistion
27th Oct 20227:00 amRNSChange of Adviser
26th Oct 20224:41 pmRNSSecond Price Monitoring Extn
26th Oct 20224:36 pmRNSPrice Monitoring Extension
3rd Oct 20224:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20224:35 pmRNSPrice Monitoring Extension
3rd Oct 20222:06 pmRNSSecond Price Monitoring Extn
3rd Oct 20222:00 pmRNSPrice Monitoring Extension
3rd Oct 202211:06 amRNSSecond Price Monitoring Extn
3rd Oct 202211:01 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.